We first reported a novel palmitoylation site of MST1 at C699 in NSCLC cells, and osimertinib-resistant NSCLC cells exhibited increased depalmitoylation, implying the involvement of MST1 depalmitoylation in osimertinib resistance. The gene discussed is MST1; the disease is non-small cell lung carcinoma.